Shengming Yin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shengming Yin has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Zhaoyang Xiao
Department of Anesthesiology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China
12 shared publications Deqin Yu
College of Basic Medical Sciences, Dalian Medical University, Dalian, Liaoning, China
11 shared publicationsYiyuan Tang
College of Health Solutions, Phoenix, AZ, United States
10 shared publicationsHong Xu
College of Basic Medical Sciences, Dalian Medical University, Dalian, China
9 shared publicationsJinying Li
Department of Anesthesiology, the Second Affiliated Hospital of Dalian Medical University, Dalian 116027, China
9 shared publicationsYing Xue
College of Basic Medical Sciences, Dalian Medical University, Dalian, China
9 shared publications
Latest Publications
- Open Access
- 18 August 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 1-12
NDUFB9 ameliorates CUMS-induced depression-like behavior by promoting mitophagy
Major depressive disorder (MDD) is characterized by persistent low mood and anhedonia. Mitochondrial dysfunction is linked to MDD, but the mechanisms are unclear. In this study, transcriptomic analysis of MDD patients’ peripheral blood found three key genes: TFAM, SURF1, and NDUFB9. Single-cell transcriptomic analysis of the prefrontal cortex (PFC) in MDD patients identified seven cell types. Analysis showed strong interactions between excitatory and inhibitory neurons in the PFC, with the three genes mainly in inhibitory neurons and NDUFB9 having the highest expression. We then established a chronic unpredictable mild stress (CUMS) mouse model. CUMS exposure induced depressive-like behaviors in mice, as evidenced by decreased sucrose preference, increased immobility time in the forced swim, and reduced activity and frequency of entries into the central area in the open field. Moreover, CUMS-exposed mice exhibited mitochondrial dysfunction in the prefrontal cortex (PFC). Notably, the expressions of TFAM, SURF1, and NDUFB9 were decreased in the PFC of CUMS mice, with the most significant decrease observed in NDUFB9. Subsequently, the overexpression of NDUFB9 in CUMS-treated mice significantly alleviated depressive-like behaviors, restored mitochondrial function and reduced the death of inhibitory neurons. It also enhanced mitophagy by PINK1/Parkin pathway. Inhibiting autophagy and mitophagy confirmed mitophagy’s pivotal role in NDUFB9-mediated restoration. Co-IP and protein half-life assays revealed that NDUFB9 stabilizes PINK1, thereby promoting mitophagy. In conclusion, our findings reveal a novel role of NDUFB9 on alleviating depression-like behavior by enhancing mitophagy, suggesting that targeting NDUFB9 could offer a promising therapeutic strategy for MDD.
- 18 August 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 1-12
Open AccessNDUFB9 ameliorates CUMS-induced depression-like behavior by promoting mitophagy
Major depressive disorder (MDD) is characterized by persistent low mood and anhedonia. Mitochondrial dysfunction is linked to MDD, but the mechanisms are unclear. In this study, transcriptomic analysis of MDD patients’ peripheral blood found three key genes: TFAM, SURF1, and NDUFB9. Single-cell transcriptomic analysis of the prefrontal cortex (PFC) in MDD patients identified seven cell types. Analysis showed strong interactions between excitatory and inhibitory neurons in the PFC, with the three genes mainly in inhibitory neurons and NDUFB9 having the highest expression. We then established a chronic unpredictable mild stress (CUMS) mouse model. CUMS exposure induced depressive-like behaviors in mice, as evidenced by decreased sucrose preference, increased immobility time in the forced swim, and reduced activity and frequency of entries into the central area in the open field. Moreover, CUMS-exposed mice exhibited mitochondrial dysfunction in the prefrontal cortex (PFC). Notably, the expressions of TFAM, SURF1, and NDUFB9 were decreased in the PFC of CUMS mice, with the most significant decrease observed in NDUFB9. Subsequently, the overexpression of NDUFB9 in CUMS-treated mice significantly alleviated depressive-like behaviors, restored mitochondrial function and reduced the death of inhibitory neurons. It also enhanced mitophagy by PINK1/Parkin pathway. Inhibiting autophagy and mitophagy confirmed mitophagy’s pivotal role in NDUFB9-mediated restoration. Co-IP and protein half-life assays revealed that NDUFB9 stabilizes PINK1, thereby promoting mitophagy. In conclusion, our findings reveal a novel role of NDUFB9 on alleviating depression-like behavior by enhancing mitophagy, suggesting that targeting NDUFB9 could offer a promising therapeutic strategy for MDD.
- 16 November 2023
- Published by Springer Nature in Neuroscience Bulletin
- Vol. 40 (5) , 577-593
Anti-epileptic and Neuroprotective Effects of Ultra-low Dose NADPH Oxidase Inhibitor Dextromethorphan on Kainic Acid-induced Chronic Temporal Lobe Epilepsy in Rats
Neuroinflammation mediated by microglia and oxidative stress play pivotal roles in the development of chronic temporal lobe epilepsy (TLE). We postulated that kainic acid (KA)-Induced status epilepticus triggers microglia-dependent inflammation, leading to neuronal damage, a lowered seizure threshold, and the emergence of spontaneous recurrent seizures (SRS). Extensive evidence from our laboratory suggests that dextromethorphan (DM), even in ultra-low doses, has anti-inflammatory and neuroprotective effects in many animal models of neurodegenerative disease. Our results showed that administration of DM (10 ng/kg per day; subcutaneously via osmotic minipump for 4 weeks) significantly mitigated the residual effects of KA, including the frequency of SRS and seizure susceptibility. In addition, DM-treated rats showed improved cognitive function and reduced hippocampal neuronal loss. We found suppressed microglial activation-mediated neuroinflammation and decreased expression of hippocampal gp91phox and p47phox proteins in KA-induced chronic TLE rats. Notably, even after discontinuation of DM treatment, ultra-low doses of DM continued to confer long-term anti-seizure and neuroprotective effects, which were attributed to the inhibition of microglial NADPH oxidase 2 as revealed by mechanistic studies.
- 16 November 2023
- Published by Springer Nature in Neuroscience Bulletin
- Vol. 40 (5) , 577-593
Anti-epileptic and Neuroprotective Effects of Ultra-low Dose NADPH Oxidase Inhibitor Dextromethorphan on Kainic Acid-induced Chronic Temporal Lobe Epilepsy in Rats
Neuroinflammation mediated by microglia and oxidative stress play pivotal roles in the development of chronic temporal lobe epilepsy (TLE). We postulated that kainic acid (KA)-Induced status epilepticus triggers microglia-dependent inflammation, leading to neuronal damage, a lowered seizure threshold, and the emergence of spontaneous recurrent seizures (SRS). Extensive evidence from our laboratory suggests that dextromethorphan (DM), even in ultra-low doses, has anti-inflammatory and neuroprotective effects in many animal models of neurodegenerative disease. Our results showed that administration of DM (10 ng/kg per day; subcutaneously via osmotic minipump for 4 weeks) significantly mitigated the residual effects of KA, including the frequency of SRS and seizure susceptibility. In addition, DM-treated rats showed improved cognitive function and reduced hippocampal neuronal loss. We found suppressed microglial activation-mediated neuroinflammation and decreased expression of hippocampal gp91phox and p47phox proteins in KA-induced chronic TLE rats. Notably, even after discontinuation of DM treatment, ultra-low doses of DM continued to confer long-term anti-seizure and neuroprotective effects, which were attributed to the inhibition of microglial NADPH oxidase 2 as revealed by mechanistic studies.
- 21 June 2023
- Published by Elsevier in Neuroscience
- Vol. 526, 97-106
GABAB Receptor Activation Attenuates Neuronal Pyroptosis in Post-cardiac Arrest Brain Injury
- 21 June 2023
- Published by Elsevier in Neuroscience
- Vol. 526, 97-106
GABAB Receptor Activation Attenuates Neuronal Pyroptosis in Post-cardiac Arrest Brain Injury
- Open Access
- 12 April 2023
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 11
The involvement of ADAR1 in chronic unpredictable stress-induced cognitive impairment by targeting DARPP-32 with miR-874-3p in BALB/c mice
Introduction: Chronic stress exposure is the main environmental factor leading to cognitive impairment, but the detailed molecular mechanism is still unclear. Adenosine Deaminase acting on double-stranded RNA1(ADAR1) is involved in the occurrence of chronic stress-induced cognitive impairment. In addition, dopamine and Adenosine 3′5′-monophosphate-regulated phospho-protein (DARPP-32) gene variation affects cognitive function. Therefore, we hypothesized that ADAR1 plays a key role in chronic stress-induced cognitive impairment by acting on DARPP-32.Methods: In this study, postnatal 21-day-old male BALB/c mice were exposed to chronic unpredictable stressors. After that, the mice were treated with ADAR1 inducer/inhibitor. The cognitive ability and cerebral DARPP-32 protein expression of BALB/c mice were evaluated. In order to explore the link between ADAR1 and DARPP-32, the effects of ADAR1 high/low expression on DARPP-32 protein expression in vitro were detected.Results: ADAR1 inducer alleviates cognitive impairment and recovers decreased DARPP-32 protein expression of the hippocampus and prefrontal cortex in BALB/c mice with chronic unpredictable stress exposure. In vivo and in vitro studies confirm the results predicted by bio-informatics; that is, ADAR1 affects DARPP-32 expression via miR-874-3p.Discussion: The results in this study demonstrate that ADAR1 affects the expression of DARPP-32 via miR-874-3p, which is involved in the molecular mechanism of pathogenesis in chronic unpredictable stress-induced cognitive impairment. The new findings of this study provide a new therapeutic strategy for the prevention and treatment of stress cognitive impairment from epigenetics.
- 12 April 2023
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 11
Open AccessThe involvement of ADAR1 in chronic unpredictable stress-induced cognitive impairment by targeting DARPP-32 with miR-874-3p in BALB/c mice
Introduction: Chronic stress exposure is the main environmental factor leading to cognitive impairment, but the detailed molecular mechanism is still unclear. Adenosine Deaminase acting on double-stranded RNA1(ADAR1) is involved in the occurrence of chronic stress-induced cognitive impairment. In addition, dopamine and Adenosine 3′5′-monophosphate-regulated phospho-protein (DARPP-32) gene variation affects cognitive function. Therefore, we hypothesized that ADAR1 plays a key role in chronic stress-induced cognitive impairment by acting on DARPP-32.Methods: In this study, postnatal 21-day-old male BALB/c mice were exposed to chronic unpredictable stressors. After that, the mice were treated with ADAR1 inducer/inhibitor. The cognitive ability and cerebral DARPP-32 protein expression of BALB/c mice were evaluated. In order to explore the link between ADAR1 and DARPP-32, the effects of ADAR1 high/low expression on DARPP-32 protein expression in vitro were detected.Results: ADAR1 inducer alleviates cognitive impairment and recovers decreased DARPP-32 protein expression of the hippocampus and prefrontal cortex in BALB/c mice with chronic unpredictable stress exposure. In vivo and in vitro studies confirm the results predicted by bio-informatics; that is, ADAR1 affects DARPP-32 expression via miR-874-3p.Discussion: The results in this study demonstrate that ADAR1 affects the expression of DARPP-32 via miR-874-3p, which is involved in the molecular mechanism of pathogenesis in chronic unpredictable stress-induced cognitive impairment. The new findings of this study provide a new therapeutic strategy for the prevention and treatment of stress cognitive impairment from epigenetics.
- Open Access
- 20 January 2023
- Published by Springer Nature in Neurochemical Research
- Vol. 48 (6) , 1737-1754
Blocking Two-Pore Domain Potassium Channel TREK-1 Inhibits the Activation of A1-Like Reactive Astrocyte Through the NF-κB Signaling Pathway in a Rat Model of Major Depressive Disorder
Major depressive disorder (MDD) refers to a widespread psychiatric disorder. Astrocytes play a pivotal role in regulating inflammation which is a well-acknowledged key component in depression pathogenesis. However, the effects of the neuroinflammation-inducing A1-like astrocytes on MDD are still unknown. TWIK-related K+ channel 1 (TREK-1) has been demonstrated to regulate the action of antidepressants. Nevertheless, its mechanisms and effects on A1-like astrocyte stimulation in MDD are not clear. Therefore, we conducted in vivo and in vitro experiments using TREK-1 specific inhibitor spadin. In vivo, rats were subjected to a 6-week chronic unpredictable mild stress (CUMS) followed by spadin treatment. Behavioral tests were employed to surveil depressive-like behaviors. Hippocampal proteomic analysis was carried out with the purpose of identifying differentially expressed proteins after CUMS and spadin treatments. In vitro, astrocyte-conditioned medium and spadin were used to treat rat astrocyte cell line. The activated microglia, inflammatory factors, A1 astrocyte markers, and activated nuclear factor kappa B (NF-κB) pathway were later analyzed using immunofluorescence, western blot, and RT-qPCR. Our findings indicated that blockage of TREK-1 reduced CUMS-induced depressive-like behavior in rats, inhibited the microglial stimulation, reduced inflammatory factor levels, and suppressed the activation of A1-like reactive astrocytes in the hippocampus. We also verified that the suppression of A1-like astrocytes by spadin necessitated the NF-κB pathway. According to the findings, blocking TREK-1 inhibited the activation of A1-like reactive astrocytes via the NF-κB signaling pathway in MDD. Our study preliminarily identifies a novel antidepressant mechanism of TREK-1 action and provides a therapeutic path for MDD.
- 20 January 2023
- Published by Springer Nature in Neurochemical Research
- Vol. 48 (6) , 1737-1754
Open AccessBlocking Two-Pore Domain Potassium Channel TREK-1 Inhibits the Activation of A1-Like Reactive Astrocyte Through the NF-κB Signaling Pathway in a Rat Model of Major Depressive Disorder
Major depressive disorder (MDD) refers to a widespread psychiatric disorder. Astrocytes play a pivotal role in regulating inflammation which is a well-acknowledged key component in depression pathogenesis. However, the effects of the neuroinflammation-inducing A1-like astrocytes on MDD are still unknown. TWIK-related K+ channel 1 (TREK-1) has been demonstrated to regulate the action of antidepressants. Nevertheless, its mechanisms and effects on A1-like astrocyte stimulation in MDD are not clear. Therefore, we conducted in vivo and in vitro experiments using TREK-1 specific inhibitor spadin. In vivo, rats were subjected to a 6-week chronic unpredictable mild stress (CUMS) followed by spadin treatment. Behavioral tests were employed to surveil depressive-like behaviors. Hippocampal proteomic analysis was carried out with the purpose of identifying differentially expressed proteins after CUMS and spadin treatments. In vitro, astrocyte-conditioned medium and spadin were used to treat rat astrocyte cell line. The activated microglia, inflammatory factors, A1 astrocyte markers, and activated nuclear factor kappa B (NF-κB) pathway were later analyzed using immunofluorescence, western blot, and RT-qPCR. Our findings indicated that blockage of TREK-1 reduced CUMS-induced depressive-like behavior in rats, inhibited the microglial stimulation, reduced inflammatory factor levels, and suppressed the activation of A1-like reactive astrocytes in the hippocampus. We also verified that the suppression of A1-like astrocytes by spadin necessitated the NF-κB pathway. According to the findings, blocking TREK-1 inhibited the activation of A1-like reactive astrocytes via the NF-κB signaling pathway in MDD. Our study preliminarily identifies a novel antidepressant mechanism of TREK-1 action and provides a therapeutic path for MDD.
- Open Access
- 11 September 2021
- Published by Elsevier in Neurobiology of Stress
- Vol. 15, 100396
Roles of miR-432 and circ_0000418 in mediating the anti-depressant action of ADAR1
- 11 September 2021
- Published by Elsevier in Neurobiology of Stress
- Vol. 15, 100396
Open AccessRoles of miR-432 and circ_0000418 in mediating the anti-depressant action of ADAR1
- 1 March 2021
- Published by Elsevier in Behavioural Brain Research
- Vol. 402, 113087
The involvement of ADAR1 in antidepressant action by regulating BDNF via miR-432
- 1 March 2021
- Published by Elsevier in Behavioural Brain Research
- Vol. 402, 113087
The involvement of ADAR1 in antidepressant action by regulating BDNF via miR-432
- 1 November 2020
- Published by Elsevier in Brain Research
- Vol. 1746, 146945
L-lactate preconditioning promotes plasticity-related proteins expression and reduces neurological deficits by potentiating GPR81 signaling in rat traumatic brain injury model
- 1 November 2020
- Published by Elsevier in Brain Research
- Vol. 1746, 146945
L-lactate preconditioning promotes plasticity-related proteins expression and reduces neurological deficits by potentiating GPR81 signaling in rat traumatic brain injury model
- Open Access
- 5 December 2018
- Published by PeerJ
An ADAR1 inducer attenuated the effects of social isolation on depressive-like behavior and ADAR1 (p110) in BALB/c mice
Introduction Social isolation induces depressive-like behavior in animals and humans by impacting RNA editing, but the detailed mechanisms are still unknown. The purpose of this study was to explore how an ADAR1 (RNA-editing enzyme) inducer and inhibitor may impact the isolation-induced depressive-like behavior of mice and to identify new therapeutic targets for the development of an effective solution for the recovery from depressive-like behavior in socially isolated animals and humans. Methods Twenty-one-day-old BALB/c mice with and without isolation treatment were evaluated for depressive-like behavior by open-field tests, tail suspension tests, and forced swimming tests. Immunohistochemistry and Western blots were used to measure the immunoreactivity and protein expression of ADAR1 (p110). In addition, the isolated mice were treated with an ADAR1 inducer (IFN-γ) or inhibitor (EHNA). The performance of both treatments on the behavior of and ADAR1 (p110) expression in isolated mice was examined. Results Both the immunoreactivity and protein expression of ADAR1 (p110) in the prefrontal cortex decreased in isolated BALB/c mice with depressive-like behavior compared to those of the age-matched, gregarious BALB/c mice. Additionally, the treatments with ADAR1 inducer or inhibitor improved or aggravated depressive-like behavior in isolated mice, respectively. Furthermore, the ADAR1 inducer returned the immunoreactivity and protein expression of ADAR1 (p110) back to the normal level. Conclusion The ADAR1 inducer attenuated the effects of social isolation on depressive-like behavior and ADAR1 (p110) in BALB/c mice.
- 5 December 2018
- Published by PeerJ
Open AccessAn ADAR1 inducer attenuated the effects of social isolation on depressive-like behavior and ADAR1 (p110) in BALB/c mice
Introduction Social isolation induces depressive-like behavior in animals and humans by impacting RNA editing, but the detailed mechanisms are still unknown. The purpose of this study was to explore how an ADAR1 (RNA-editing enzyme) inducer and inhibitor may impact the isolation-induced depressive-like behavior of mice and to identify new therapeutic targets for the development of an effective solution for the recovery from depressive-like behavior in socially isolated animals and humans. Methods Twenty-one-day-old BALB/c mice with and without isolation treatment were evaluated for depressive-like behavior by open-field tests, tail suspension tests, and forced swimming tests. Immunohistochemistry and Western blots were used to measure the immunoreactivity and protein expression of ADAR1 (p110). In addition, the isolated mice were treated with an ADAR1 inducer (IFN-γ) or inhibitor (EHNA). The performance of both treatments on the behavior of and ADAR1 (p110) expression in isolated mice was examined. Results Both the immunoreactivity and protein expression of ADAR1 (p110) in the prefrontal cortex decreased in isolated BALB/c mice with depressive-like behavior compared to those of the age-matched, gregarious BALB/c mice. Additionally, the treatments with ADAR1 inducer or inhibitor improved or aggravated depressive-like behavior in isolated mice, respectively. Furthermore, the ADAR1 inducer returned the immunoreactivity and protein expression of ADAR1 (p110) back to the normal level. Conclusion The ADAR1 inducer attenuated the effects of social isolation on depressive-like behavior and ADAR1 (p110) in BALB/c mice.